Siemens Healthineers Wins Dual Clearance for D-Dimer Test While Analysts Look Past the Stock's Slide

Siemens Healthineers gained CE mark and FDA 510(k) clearance for its Innovance D-Dimer 2.0 assay, but the stock fell 1.0% to EUR 37.55 as losses hit 16% YTD.

Siemens Healthineers has secured simultaneous European and American approval for a new blood test, pushing its laboratory diagnostics business onto the global stage even as its share price continues to sag.

The Innovance D-Dimer 2.0 assay carries both the CE mark for Europe and 510(k) clearance from the U.S. Food and Drug Administration, clearing the way for immediate worldwide distribution of the coagulation test. Lab diagnostics represents a key pillar for the Munich-based medtech group alongside its dominant imaging division.

Investors, however, greeted the news with little enthusiasm. The stock slipped 1.0% in early-week trading to EUR 37.55, extending a year-to-date decline that has now reached 16%. A separate reading later in the week put the shares at EUR 37.30, down 1.6% on the day, with losses since January totaling 17%.

Partnerships Extend Beyond the Product Launch

Siemens Healthineers is not relying solely on in-house development to broaden its diagnostics reach. On Thursday, the company struck a strategic alliance with Truvian Health to advance that firm's TruVerus blood-testing platform. Under the arrangement, the DAX-listed group will contribute development support, technical resources, manufacturing know-how and commercial advice, while both parties plan to jointly evaluate future diagnostic solutions.

That deal follows a September 21 collaboration with Novo targeting the liver conditions MASLD and MASH. The partnership focuses on earlier risk detection and improved access to non-invasive blood tests. Such tie-ups form part of management's broader effort to bind diagnostics and imaging more tightly to therapeutic applications, using technological differentiation to defend market share in core clinical areas.

Radiotherapy Platform Draws Analyst Attention

Roughly a week before the D-Dimer announcement, Siemens Healthineers used the ASTRO annual meeting in Boston to unveil Accela, its new radiotherapy system. Built on the NeoArc architecture, the platform is designed to deliver stereotactic treatments during a single breath-hold and to perform high-precision irradiation at multiple sites within 60 seconds. Commercial launch remains contingent on outstanding regulatory approvals.

The efficiency gains promised by those shorter treatment times have resonated with analysts. David Adlington of JPMorgan rated the stock "Overweight" on September 29 with a price target of EUR 57.40, pointing specifically to the workflow improvements Accela could deliver for clinics. Julien Dormois at Jefferies reaffirmed his buy recommendation on September 30 — a call reported in the media as confirmed the following Wednesday — with a EUR 50 target, citing signs of accelerating momentum in imaging and precision therapy for the closing quarter. He also cautioned that the diagnostics segment is likely to keep contracting.

Eurospine Congress Offers Next Stage

Attention now shifts to Gothenburg, where the Eurospine specialist congress runs from October 7 to 9. The gathering gives Siemens Healthineers a platform to deepen dialogue with clinicians and sharpen its positioning in modern treatment approaches.

What investors ultimately want is hard evidence that the various divisions are delivering. That verdict arrives on November 5, when the company publishes fourth-quarter and full-year figures. One source lists the reporting date as November 5, 2026; the other as November 5 of the current year. Either way, the release will show how well the segments have matched expectations — and whether the product pipeline can finally reverse the stock's fortunes.